Anticancer drugs effects on glucose metabolism
Class/Agent | Glycaemia | HbA1c | c-peptide/insulin | Mechanisms |
---|---|---|---|---|
Hormonal agents - GnRH agonists (triptorelin, leuprorelin) - Anti-androgens (cyproterone acetate, flutamide, bicalutamide, nilutamide) | ↑ [73] | ↑ [78] | Increased Ins-Res | |
Glucocorticoids (prednisone, prednisolone, methylprednisolone, dexamethasone) | ↑ [80, 81] | ↑ [67, 81] | Increased Ins-Res | |
mTOR inhibitors (everolimus, sirolimus, temsirolimus) | ↑ [87] | ↑ [67] | Increased Ins-Res | |
ICIs - Anti-CTLA-4 antibodies (ipilimumab) - PDL-1 inhibitors (atezolizumab, avelumab) - PD-1 inhibitors (nivolumab, pembrolizumab) | ↑ [89] | ↑ [89] | ↓ [89] | Reduced IP/S |
Somatostatin analogues (octreotide, lanreotide, pasireotide) | ↑ (pasireotide) [93]↓ (octreotide) [94] | ↑ [93] | Reduced IP/SReduced GP/S | |
L-asparaginase | ↑ [95, 96] | Reduced IP/S | ||
Alkylating agents (cisplatin, carboplatin, oxaliplatin, cyclophosphamide, etc.) | ↑ [97–99] | ↑ [67] | Reduced IP/S | |
Anti-microtubules (docetaxel, paclitaxel, vinorelbine, vincristine, etc.) | ↑ [97, 100] | ↑ [67] | Reduced IP/S | |
Antimetabolites (5-fluorouracil, gemcitabine, capecitabine, methotrexate, etc.) | ↑ [98, 101] | ↑ [67] | ↓ [101] | Reduced IP/S |
Antracyclines (doxorubicin, epirubicin, etc.) | ↑ [97] | Reduced IP/S |
indicates the uncertainty of the evidence on this item; GnRH: gonadotropin-releasing hormone; Ins-Res: insulin resistance; HbA1c: glycated haemoglobin; mTOR: mammalian target of rapamycin; ICIs: immune checkpoint inhibitors; CTLA-4: cytotoxic T-lymphocyte 4-antigen; PDL-1: programmed cell death ligand-1; PD-1: programmed cell death-1; IP/S: insulin production/secretion; GP/S: glucagon production/secretion
The authors gratefully acknowledge professor Giuliana Arcidiacono, English and Anglo-American language PhD., University of Catania, for the language revision of the manuscript.
AM wrote the first draft of the manuscript; PV, FM, RV, and LS wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2020.